We investigate molecular mechanisms and therapeutic strategies for frontotemporal dementia and amyotrophic lateral sclerosis at the UCL Institute of Neurology and the UK Dementia Research Institute at UCL.
Find out more on our research page.
News
We developed new polyGR and polyPR knock-in mice that developed features of ALS and surprisingly had a neuroprotective extracellular matrix response. An epic effort by lead author Carmelo and many lab members and collaborators including Elizabeth Fisher at UCL. Covered by Alzforum: https://www.alzforum.org/news/research-news/neuroprotective-extracellular-matrix-seen-c9orf72-alsftd-models and more info here: https://ukdri.ac.uk/news-and-events/protective-response-to-early-changes-in-als-and-ftd
We are excited to be presenting at the largest international conference on ALS. Alex will present our exciting new data on lipid dysregulation in ALS and Adrian on FTD/ALS modelling and therapeutics.
Rubika collaborated with the Ule lab to identify the RNA transcripts bound by C9orf72 polyPR in cells. We hope this will be a useful resource for the field, all the data is freely available: https://www.life-science-alliance.org/content/6/9/e202201824 With co-first author Igor Ruiz de los Mozos they identified the GAAGA pentamer to be…
Ashling was selected to give a talk at the GRS on ALS in Les Diablerets in Switzerland in July 2023. She presented her exciting data on neuronal lipid homeostasis in C9orf72 FTD/ALS.
Alex gave a short talk at the MNDA EnCouRage meeting in June 2023, an MND patient-facing meeting for ECRs hosted by the MNDA. Thanks to the MNDA for putting on this insightful event. https://www.mndassociation.org/research/research/mnd-encourage-uk-2023